| HOME >> BIOLOGY >> TECHNOLOGY |
PARSIPPANY, N.J., Sept. 10 /PRNewswire/ -- Ferring Pharmaceuticals Inc., a specialty pharmaceutical company, announces the appointment of Paul Korner, M.D., M.B.A. as Vice President, Medical Affairs. Dr. Korner will be responsible for Medical Affairs for Ferring's Infertility, Orthopaedics, Urology, and Gastroenterology therapeutic areas as well as Product Safety.
"As a result of our continued and projected growth, we have expanded and realigned our management staff to best meet our business needs," said Wayne Anderson, President and CEO. "Dr. Korner is exceptionally well qualified to fill this new role, as we continue our quest to achieve rapid new drug approvals by identifying, improving and commercializing late-stage or marketed products in our clinical specialty areas."
Dr. Korner joins Ferring with a broad range of experience in medical affairs, clinical development, management and business development. Prior to joining Ferring, Dr. Korner was Vice President of Medical Affairs, Women's Healthcare at Bayer HealthCare Pharmaceuticals, where his group supported the U.S. Women's Healthcare business unit, and managed medical experts supporting Phase II and III development projects. He has also served as Executive Director of Medical Affairs, Female Healthcare at Berlex Laboratories, Inc., and Senior Director of Clinical Research and Development, Women's Health and Bone Repair for Wyeth Research.
Dr. Korner is a board certified obstetrician and gynecologist. He received his M.D. from Loyola University, Stritch School of Medicine near Chicago. He also holds an M.B.A. from the Michael J. Coles College of Business at Kennesaw State University in Georgia.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately
owned, international pharmaceutical company. Ferring's line of products
includes: EUFLEXXA(R) (hyaluronic acid) for pain from osteoarthritis in the
knee; BRAVELLE(R) (urofollitr
'/>"/>
| SOURCE Ferring Pharmaceuticals Inc. Copyright©2008 PR Newswire. All rights reserved |